Investment Rating - The report maintains a "Buy" rating for Innovent Biologics [12]. Core Insights - The first-generation immune checkpoint inhibitors (IO therapies) are facing patent expirations between 2028 and 2032, creating a significant demand for second-generation IO therapies, which are projected to have a market size of approximately $200 billion [4][7]. - The first-generation PD-1 inhibitors, represented by Keytruda (pembrolizumab) and Opdivo (nivolumab), achieved global sales of $46 billion in 2023, with an expected increase to $52.5 billion in 2024, reflecting a year-on-year growth of 18% [7][20]. - IBI363, developed by Innovent Biologics, demonstrates Best-in-Class potential through its unique PD-1 monoclonal antibody/IL-2 fusion design, showing promising results in treating both hot and cold tumors [9][68]. Summary by Sections Second-Generation IO Therapies - The second-generation IO market is categorized into three segments: replacement of first-generation IO, addressing resistance in first-generation IO, and targeting cold tumors, with a total potential market size estimated at $200 billion [7][49]. - The report highlights the urgency for multinational corporations (MNCs) to secure their positions in the next-generation cornerstone cancer therapies as first-generation patents expire [4][7]. IBI363 Molecular Design - IBI363 employs a unique PD-1 monoclonal antibody and IL-2 fusion design, achieving dual activation of effector T cells by "releasing the brake" and "pressing the accelerator" [8][56]. - The drug features a globally innovative α-biased IL-2 design, which reduces peripheral toxicity while enhancing therapeutic efficacy [57][62]. Clinical Performance of IBI363 - IBI363 has shown significant clinical benefits in various tumor types, including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC), with promising long-term overall survival (OS) trends [9][68]. - In clinical trials, IBI363 demonstrated a confirmed objective response rate (ORR) of 36.7% and a disease control rate (DCR) of 90% in squamous NSCLC patients, with a median progression-free survival (mPFS) of 9.3 months [69].

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Views - The market is experiencing high volatility with significant sector differentiation, particularly with innovative drugs performing strongly while the automotive sector has seen notable declines [1][2] - Overall, the Hang Seng Index increased by 0.4%, while the Hang Seng Technology Index decreased by 0.9% [1] - The report highlights that 19 industries within the Hong Kong Stock Connect saw gains, while 11 experienced losses, with the most significant increases in the comprehensive, pharmaceutical, and defense sectors [1] Summary by Sections Market Performance - The Hang Seng Index closed at 23,893, reflecting a weekly increase of 0.4% and a year-to-date increase of 19.1% [12] - The small-cap stocks outperformed mid and large-cap stocks, with the Hang Seng Small Cap Index rising by 4.5% [1] Fund Flow - There was a significant outflow of funds from the automotive sector, with an average daily outflow of HKD 17.7 billion, while the pharmaceutical sector saw an inflow of HKD 4.8 billion [2] - The overall average daily fund intensity for Hong Kong Stock Connect components was -8.0 billion HKD, indicating a shift from the previous week’s positive inflow [2] Earnings Forecast - The report indicates a substantial upward revision in earnings per share (EPS) expectations, particularly for the automotive sector, which saw a 24.3% increase [3] - In total, 26 industries had their EPS forecasts revised upward, while only 3 experienced downward revisions [3] Sector Performance - The comprehensive sector led with a 19.2% increase, followed by pharmaceuticals at 8.5% and defense at 8.1% [16] - The automotive sector, however, faced a decline of 4.4%, reflecting ongoing challenges within the industry [16]

Investment Rating - The report maintains a "Positive" investment rating for the industry [8]. Core Insights - IL-25 is identified as a novel target in the Type II inflammation pathway, showing upregulation in atopic dermatitis (AD), psoriasis, and contact dermatitis, indicating its involvement in the progression of these skin inflammatory diseases [2][5][27]. - The drug SM17, developed by Chinese Antibody, is a first-in-class (FIC) IL-17RB monoclonal antibody targeting IL-25, demonstrating promising proof-of-concept (PoC) data in Phase Ib trials for atopic dermatitis, with superior itch relief compared to existing therapies [6][35][42]. Summary by Sections IL-25 as a Target - IL-25, a member of the IL-17 cytokine family, plays a crucial role in host defense and inflammatory diseases, inducing the production of IL-4, IL-5, and IL-13, while inhibiting Th17 differentiation [5][17]. - The upregulation of IL-25 in various skin inflammatory diseases suggests its potential for multi-indication exploration [27]. SM17 Clinical Data - In the Phase Ib trial, 75% of patients in the high-dose group achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) by week 12, compared to 0% in the placebo group, indicating a significant difference of 75% [6][35]. - The high-dose group also showed that 91.7% of patients had a significant reduction in the Peak Pruritus Numeric Rating Scale (PP-NRS) score, with no responders in the placebo group [7][38]. - SM17 demonstrated rapid and deep itch relief, outperforming existing AD therapies while maintaining comparable skin lesion improvement [41][43]. Competitive Landscape - Currently, only two IL-25-targeting candidates, SM17 and XKH001, are in clinical development, indicating a relatively early stage of research for this target compared to more established pathways like IL-17 and IL-4 [6][33]. - The competitive landscape for IL-25 and IL-17RB-targeting drugs is evolving, with several candidates in various stages of development [34].

M&A Dynamics - From June 3 to June 8, there were 63 merger and acquisition (M&A) events involving listed companies, with 16 classified as significant M&A events[9] - Out of the total M&A events, 9 were completed, including 1 significant M&A[9] Policy Updates - The People's Bank of China emphasized the need to optimize systems for listings, M&A, and equity incentives based on technological innovation characteristics[7] - The Shanghai Stock Exchange plans to encourage listed companies to increase dividend payouts and enhance market value management tools[7] Major M&A Events - Notable M&A transactions included Baota Industrial acquiring 100% of Electric Power Investment New Energy for CNY 80,927,000[13] - A total of 4 M&A events involved state-owned enterprises as acquirers during the reporting period[13] M&A Failures - There were 3 failed M&A attempts, including a significant transaction by Guangdong Hongyuan due to a lack of consensus on the final transaction plan[15][17] - The failed transactions involved a total value of CNY 19,800,000 for one of the deals[17] Control Changes - Three companies reported changes in actual control, including Jinzi Ham and Diou Home, with the changes occurring between May 30 and June 5, 2025[19] Market Performance - The restructuring index underperformed the Wind All A index by -0.12% during the reporting period[21] - Over a mid-term view, the restructuring index showed fluctuations within a positive range compared to the Wind All A index[21] Risk Factors - Economic recovery in China is slower than expected, which may increase market uncertainty[26] - Geopolitical risks and uncertainties regarding U.S. policies towards China could negatively impact A-share liquidity[26]

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The Hong Kong stock market has shown a positive trend with the Hang Seng Index and Hang Seng Tech both increasing by 2.2% this week, indicating a strong performance in the innovation drug and internet sectors [1][12] - There has been a significant inflow of funds into Hong Kong stocks, particularly in the media and pharmaceutical sectors, with an average daily fund strength of +7.4 million HKD, a notable increase from the previous week [2] - Earnings per share (EPS) expectations for the Hong Kong stock market have been revised upward by 0.3%, with the electronics sector leading the revisions [3] Summary by Sections Market Performance - The Hang Seng Index closed at 23,793, reflecting a weekly increase of 2.2% and a year-to-date increase of 18.6% [12] - The performance of various sectors shows that the innovation drug sector rose by 6.1%, while the internet sector increased by 3.5% [1] Fund Flow Analysis - A total of 23 sectors experienced fund inflows, with media and pharmaceuticals seeing the highest inflows of +1.9 million HKD and +1.4 million HKD per day, respectively [2] - The sectors that faced outflows included transportation and home appliances, each with a daily outflow of -0.1 million HKD [2] Earnings Forecast - The overall EPS forecast for the Hong Kong stock market has been adjusted upward by 0.3%, with the electronics sector seeing a 1.1% increase in EPS expectations [3] - The steel sector, however, faced a significant downward revision of -7.7% in EPS expectations [3]

Market Overview - The US stock market experienced declines ahead of the Memorial Day holiday, with the Dow Jones falling 256 points or 0.61% to close at 41,603 points, marking four consecutive days of losses[10] - European markets also weakened, with the Stoxx 600 index dropping 0.93% due to renewed trade tensions following Trump's tariff threats against the EU[10] Currency and Commodities - The US dollar index decreased by 0.8%, reflecting an 8.6% decline year-to-date, while gold prices rose by 2.1% to $3,394.50 per ounce amid increased safe-haven demand[27][28] - Oil prices saw a slight increase, with NY crude oil rising 0.5% to $61.53 per barrel, as market confidence in a potential US-Iran nuclear deal weakened[28] Fixed Income - US Treasury yields fell significantly, with the 10-year yield dropping to 4.51%, a decrease of 1.8 basis points, as investors sought safety amid escalating trade tensions[32] - Asian investment-grade bonds remained strong, with Chinese investment-grade bond spreads narrowing by 2-5 basis points, driven by demand from major companies like Alibaba and Tencent[32] Sector Performance - In the Chinese A-share market, the Shanghai Composite Index fell 0.94% to 3,348 points, with over 4,200 stocks declining, while the healthcare sector showed resilience[16] - The Hong Kong market displayed mixed results, with the Hang Seng Index rising 0.24% and healthcare stocks leading gains, while technology stocks faced pressure[12] Key Corporate Developments - Trump's threats of a 50% tariff on EU imports and pressure on Apple to shift production to the US contributed to market volatility, impacting major tech stocks like Apple, which fell 3.02%[10][12] - Xpeng Motors' new MONA series is expected to significantly boost sales, with projections of 600,000 units contributing to a 10% market share in the 100,000-150,000 RMB price range[8]

一方面，科创板公司出口产品具有鲜明的高毛利率特征。据统计，科创板公司境外销售毛利率中位数达 到40.8%，高于板块整体毛利率水平，这有力印证了凭借创新获取 "溢价" 的竞争策略行之有效。例如， 清越科技抓住海外客户追求PMOLED产品新、奇、特的需求加强产品定制，其境外销售毛利率比境内 销售毛利率高出近25个百分点。 面对全球化浪潮中的波折，科创板公司守正创新，坚定不移实施"出海"战略，汇聚全球资源提升核心竞 争力。2024年，科创板公司境外收入突破4300亿元，同比增长6.1%。高附加值产品出口、技术与资本 并驾齐驱的"出海"模式，渐成科创板公司高质量发展新支点。 境外市场增长动能澎湃 从年报披露情况看，2024年，科创板近八成公司实现境外销售，境外收入合计4303.61亿元，占板块整 体营业收入的三成。境外收入同比增速6.1%，超过板块整体营业收入增速。其中，近四成公司2024年 海外收入同比增幅超过其营业收入总体增幅，173家公司境外收入同比增长超过30%，54家公司境外收 入在10亿元以上。 境外收入增长亮眼，既有海外版图的横向拓展，也不乏细分市场的纵向渗透。据统计，63家科创板公司 产品远销逾50个 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the performance of the Hong Kong stock market (港股) in 2024, highlighting a recovery trend in overall earnings growth with a 1.2% increase in revenue and a 9.8% year-on-year growth in net profit attributable to shareholders [1][3][6]. Core Insights and Arguments - **Earnings Growth**: The second half of 2024 saw a significant acceleration in earnings, with a year-on-year increase of 13.3% [1][6]. - **Key Sectors Driving Growth**: - The information technology sector benefited from breakthroughs in AI technology, with net profit growth of 77.4% in the software and services sub-sector and 76.4% in the technology hardware and equipment sub-sector [1][10]. - The financial sector, particularly the insurance industry, experienced a 70.8% increase in net profit, while diversified financial services saw a 20.5% growth [1][10]. - The healthcare sector, including pharmaceuticals, biotechnology, and life sciences, improved profitability by nearly 20 percentage points [1][10]. - **Struggling Sectors**: The consumer sector showed weak growth, with significant declines in return on equity (ROE) for household and personal products, and food retail. The optional consumer retail sub-sector's profit growth decreased by 36 percentage points, while media and consumer services saw declines of approximately 18% and 19% respectively [1][11]. Financial Metrics - **Return on Equity (ROE)**: The ROE for Hong Kong stocks rose to 7% in 2024, up from 6.7% in the first half of the year, but still below the average of around 10% since 2016. The DuPont analysis indicated that the increase in asset turnover was the primary driver of the ROE improvement [1][7][8]. - **Revenue Trends**: The revenue growth rate for Hong Kong stocks showed signs of bottoming out, with a 1.2% increase for the year, slightly down from 1.9% in the first half of 2024 [1][5]. Comparative Analysis - **Performance vs. A-shares**: The earnings recovery speed of Hong Kong stocks is superior to that of A-shares, which reported negative growth rates of -0.2% for the year and -0.5% for the first half of 2025 in terms of revenue and -2.7% for both periods in net profit [4][6]. Future Outlook - **Support Factors for 2025**: The global technology cycle is expected to rebound, with the AI-driven industrial revolution continuing to support the performance of the information technology sector. Additionally, macroeconomic policies aimed at stabilizing growth are anticipated to benefit mainland companies, which constitute over 60% of the market [4][12].

[Table_Info1] 证券研究报告 [Table_Title] 证券研究报告 / 债券研究报告 2025 年 5 月十大转债 报告摘要： [Table_Summary] 5 月十大转债如下： 中证转债指数 [Table_Report] 相关报告 《2025 年 4 月转债新券点评合集》 --20250430 《特朗普还有哪些牌？》 --20250428 《转债市场一周回顾（2025/04/21-2025/04/25）》 --20250427 《关税冲击逐步显现，"四稳"兜牢民生底线— —政策及基本面周度观察（20250426）》 --20250427 《【东北资产配置】政策博弈期，大类资产怎么 看？——东北证券大类资产配置报告（第 5 期）》 --20250425 首席分析师：刘哲铭 执业证书编号：S0550524040002 18801785199 liuzm1@nesc.cn 证券分析师：薛进 [Table_Invest] [Table_Author] ① 中特转债（AAA，4 月末收盘价 107.723 元，转股溢价率 111.03%， 正股 PE-TTM 11.5） ② 山路转债（AAA，4 月 ...